Skip to main content
Premium Trial:

Request an Annual Quote

MRC Holland Gets CE-IVD Mark for Spinal Muscular Atrophy Assay

NEW YORK (GenomeWeb) — Dutch biotech firm MRC Holland said recently that it has received CE-IVD marking for its SALSA MC002 assay for spinal muscular atrophy (SMA) screening in newborns. It added it has launched the test.

SMA is a neuromuscular disease caused by mutations in the SMN1 gene. According to MRC Holland, the melt curve analysis-based assay is designed to detect the presence or absence of SMN1 exon 7 in newborns. It does not require DNA purification and can provide results from dried blood spot card punches in around four hours.

MRC Holland noted that the market for SMA screening has increased with the 2016 approval of Biogen Idec's treatment Spinraza (nusinersen), which is administered before symptoms appear.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.